The patent protection landscape’s been turned on its head in the past couple years, ever since the Leahy-Smith America Invents Act went into effect. A discussion at trade group Biocom’s DeviceFest in San Diego this week addressed some of these changes and subtleties as they apply to medical device companies: “Gone are the days of storing the notes of […]
Industry and the American public have lost faith in the federal agency in charge of overseeing the country's drug and medical device industry, according to an annual survey by PricewaterhouseCoopers LLP. The pollsters found that slightly more than half (51 percent) expressed a favorable opinion of the Food & Drug Administration's performance, but that high-profile drug recalls had damaged confidence in the watchdog agency.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.